Neoadjuvant AXITINIB plus AVELUMAB for patients with localized RCC and a moderate to high risk of recurrence (N17JAV)

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515825-27-00

Enrollment

Registered

2024-07-11

Start date

Unknown

Completion date

Unknown

Last updated

2024-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal cell carcinoma

Brief summary

The primary endpoint of this study is the rate of partial remission following neoadjuvant axitinib and avelumab.

Detailed description

Safety and adverse events of the combination of axitinib with avelumab, Long term follow up with DFS, OS, rate of metastasis and local recurrence, Clavien Dindo classification of surgical morbidity, Translational research

Interventions

DRUGBavencio 20 mg/mL concentrate for solution for infusion

DRUGInlyta 5 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary endpoint of this study is the rate of partial remission following neoadjuvant axitinib and avelumab.	—

Secondary

Measure	Time frame
Safety and adverse events of the combination of axitinib with avelumab, Long term follow up with DFS, OS, rate of metastasis and local recurrence, Clavien Dindo classification of surgical morbidity, Translational research	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026